The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials
Open accessAbstract
OBJECTIVE: To evaluate the effects of belimumab versus placebo, plus standard systemic lupus erythematosus (SLE) therapy, on organ domain-specific SLE disease activity. METHODS: Data obtained after 52 weeks of treatment from two phase III trials (BLISS-52 and BLISS-76) comparing belimumab 1 and 10 mg/kg versus placebo, plus standard therapy, in 1684 autoantibody-positive patients were analysed post hoc for changes in British Isles Lupus Assessment Group (BILAG) and Safety of Estrogens in Lupus National Assessment-Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) organ domain scores. RESULTS: At baseline, the domains involved in the majority of patients were musculoskeletal and mucocutaneous by both BILAG and SELENA-SLEDAI, and immunological by SELENA-SLEDAI. At 52 weeks, significantly more patients treated with belimumab versus placebo had improvement in BILAG musculoskeletal and mucocutaneous domains (1 and 10 mg/kg), and in SELENA-SLEDAI mucocutaneous (10 mg/kg), musculoskeletal (1 mg/kg) and immunological (1 and 10 mg/kg) domains. Improvement was also observed in other organ systems with a low prevalence (≤16%) at baseline, including the SELENA-SLEDAI vasculitis and central nervous system domains. Significantly fewer patients treated with belimumab versus placebo had worsening in the BILAG haematological domain (1 mg/kg) and in the SELENA-SLEDAI immunological (10 mg/kg), haematological (10 mg/kg) and renal (1 mg/kg) domains. CONCLUSIONS: Belimumab treatment improved overall SLE disease activity in the most common musculoskeletal and mucocutaneous organ domains. Less worsening occurred in the haematological, immunological and renal domains.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Derivation of the sledai. A disease activity index for lupus patients
Bombardier, C., Gladman, D. D., Urowitz, M. B., Caron, D., Chang, C. H., Austin, A., Bell, A., Bloch, D. A., Corey, P. N., Decker, J. L., et al. (1992) · Arthritis & Rheumatism · doi:10.1002/art.1780350606 · Cited by 4,570
Self-citationNavarra, S. V., Guzmán, R. M., Gallacher, A. E., Hall, S., Levy, R. A., Jimenez, R. E., Li, E. K.-M., Thomas, M., Kim, H.-Y., León, M. G., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61354-2 · Cited by 2,074
Self-citationFurie, R., Petri, M., Zamani, O., Cervera, R., Wallace, D. J., Tegzová, D., Sanchez-Guerrero, J., Schwarting, A., Merrill, J. T., Chatham, W. W., et al. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30613 · Cited by 1,683
Self-citationRahman, A., & Isenberg, D. A. (2008) · New England Journal of Medicine · doi:10.1056/nejmra071297 · Cited by 1,632
Combined Oral Contraceptives in Women with Systemic Lupus Erythematosus
Petri, M., Kim, M. Y., Kalunian, K. C., Grossman, J., Hahn, B. H., Sammaritano, L. R., Lockshin, M., Merrill, J. T., Belmont, H. M., Askanase, A. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051135 · Cited by 1,166
Self-citationRahman, M. U. (2008) · Essentials of Physical Medicine and Rehabilitation · doi:10.1016/b978-1-4160-4007-1.50153-x · Cited by 1,019
Schned, E. S., Glickstein, S. L., & Anne Doyle, M. T. (1993) · Arthritis & Rheumatism · doi:10.1002/art.1780360623 · Cited by 725
Manson, J. J., & Rahman, A. (2006) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-1-6 · Cited by 605
Gordon, C., Li, C. K., & Isenberg, D. A. (2010) · Medicine · doi:10.1016/j.mpmed.2009.10.006 · Cited by 565
Novel evidence‐based systemic lupus erythematosus responder index
Furie, R. A., Petri, M. A., Wallace, D. J., Ginzler, E. M., Merrill, J. T., Stohl, W., Chatham, W. W., Strand, V., Weinstein, A., Chevrier, M. R., et al. (2009) · Arthritis Care & Research · doi:10.1002/art.24698 · Cited by 490
Self-citation
Cited by
2019 update of the EULAR recommendations for the management of systemic lupus erythematosus
Fanouriakis, A., Kostopoulou, M., Alunno, A., Aringer, M., Bajema, I., Boletis, J. N., Cervera, R., Doria, A., Gordon, C., Govoni, M., et al. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-215089 · Cited by 2,011
Self-citationManagement strategies and future directions for systemic lupus erythematosus in adults
Durcan, L., O'Dwyer, T., & Petri, M. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30237-5 · Cited by 648
Self-citationNovel paradigms in systemic lupus erythematosus
Dörner, T., & Furie, R. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30546-x · Cited by 565
Self-citationWallace, D. J., Furie, R. A., Tanaka, Y., Kalunian, K. C., Mosca, M., Petri, M. A., Dörner, T., Cardiel, M. H., Bruce, I. N., Gomez, E., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31363-1 · Cited by 513
Self-citationHoffman, W., Lakkis, F. G., & Chalasani, G. (2016) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.09430915 · Cited by 482
Metadata
- Authors
- Manzi, S., Sánchez-Guerrero, J., Merrill, J. T., Furie, R., Gladman, D., Navarra, S. V., Ginzler, E. M., D'Cruz, D. P., Doria, A., Cooper, S., Zhong, Z. J., Hough, D., Freimuth, W., & Petri, M. A.
- Venue
- Annals of the Rheumatic Diseases
- Publisher
- Elsevier BV
- Published
- 2012-11
- Volume
- 71
- Issue
- 11
- Pages
- 1833-1838
- ISSN
- 0003-4967 (ISSN-L)
- OpenAlex
- W2170524712
- Cited by
- 411
- References
- 17
- FWCI
- 28.74
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. https://app.cochat.ai/papers/10.1136/annrheumdis-2011-200831
- The paper
- Manzi, S., Sánchez-Guerrero, J., Merrill, J. T., Furie, R., Gladman, D., Navarra, S. V., Ginzler, E. M., D'Cruz, D. P., Doria, A., Cooper, S., Zhong, Z. J., Hough, D., Freimuth, W., & Petri, M. A. (2012). Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2011-200831
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.